From Our Perspective: FDA Holds Workshop to Discuss the Safe Use of Benzodiazepines - Drug Information Update

If your email program has trouble displaying this email, view it as a web page. From Our Perspective: FDA Holds Workshop to Discuss the Safe Use of Benzodiazepines FDA continues to focus on the safe use of benzodiazepines. One of the agency's initiatives on this important topic was to host a two-day virtual workshop this past summer with Duke-Margolis Center for Health Policy. This workshop brought together regulators, academic researchers, clinicians, patient advocates, and other stakeholders to share data underlying our benzodiazepine activities and to gather further input related to safe use, including current prescribing and tapering approaches. Participants also wanted to identify any gaps that may exist in clinician and patient education.   In this From Our Perspective, Marta Sokolowska, PhD, Associate Director for Controlled Substances in FDA's Center for Drug Evaluation and Research, discusses the FDA and Duke-Margolis workshop and FDA's other actions to ensure the safe use of benzodiazepines.   Learn More This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO- FDA (1-888-463-6332) or 301-796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at: druginfo@fda.hhs.gov. Stay Connected with U.S. Food and Drug Administration:         SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA